What is Savonix?
Founded in 2014 and headquartered in San Francisco, Savonix Inc. operates at the intersection of neurology and digital health. The company has developed a sophisticated, evidence-based digital neuro-cognitive assessment platform that provides healthcare providers, payers, and researchers with actionable data. By digitizing cognitive testing, Savonix replaces traditional, time-intensive clinical evaluations with a scalable, mobile-first solution. This technological shift is essential for improving treatment outcomes and enabling personalized medicine, positioning the firm as a key player in the global digital therapeutics market. The company's platform is designed to integrate seamlessly into existing clinical workflows, ensuring that cognitive health metrics are as accessible as standard vital signs.
How much funding has Savonix raised?
Savonix has raised a total of $16.6M across 3 funding rounds:
Angel/Seed
$1.5M
Series A
$14.7M
Debt
$350K
Angel/Seed (2015): $1.5M with participation from Kickstart Seed Fund
Series A (2019): $14.7M led by Rethink Impact, Fusion Fund, Wavemaker Partners, DEFTA Partners, and DigiTx Partners
Debt (2020): $350K supported by PPP
Key Investors in Savonix
Rethink Impact
Rethink Impact is a venture capital firm that invests in entrepreneurs and technology platforms focused on creating ecosystems of change, specifically targeting leaders who utilize technology to address significant global challenges in healthcare and mental health.
Wavemaker Partners
Wavemaker Ventures is a leading venture capital firm specializing in early-stage investments in Enterprise, Deep Tech, and Sustainability sectors, with a strong focus on driving positive social impact through innovative startups.
DEFTA Partners
DEFTA Partners is a global venture investment firm focusing on innovative technologies in healthcare and information and communication technology, aiming to enhance patient lives through advanced therapeutics and health ICT.
What's next for Savonix?
With the backing of major institutional investors, Savonix is well-positioned to scale its enterprise-level operations and expand its footprint in the global healthcare market. The current funding context suggests a strategic pivot toward broader clinical adoption and the enhancement of its proprietary data analytics engine. As the demand for remote patient monitoring and digital health interventions continues to rise, Savonix is expected to prioritize the integration of its cognitive assessment tools into large-scale health systems and research initiatives. Future growth will likely focus on deepening its evidence base, securing additional regulatory milestones, and expanding its reach to address the growing global burden of cognitive-related health challenges.
See full Savonix company page
